VCYT Veracyte Inc
P/E
30.8
Forward P/E
23.58
Price/Sales
6.17
Beta
1.947
Div Yield
--
Market Cap
--
Company Analysis
Latest News
🔴 Veracyte falls 4.3% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Veracyte Acquires Convergent Genomics for $150M to Expand Urology Diagnostics Portfolio
Veracyte (VCYT) announced it has completed the acquisition of Convergent Genomics, a diagnostics company focused on bladder cancer. The acquisition expands...
🔴 Veracyte is trading 4% down today after hotter-than-expected producer inflation
Veracyte is trading 4% down now at $42.10 after hotter-than-expected producer inflation and reduced expectations for near-term Federal Reserve easing. - The...